Skip to content
← Full study record

NCT00652626 · OUTCOME

Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function · Source last updated 2019-11-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
liters/hour
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

What was measured

The apparent total clearance of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated as Dose/AUC0-inf.

Analysis population: Pharmacokinetic Population, consisting of all participants with evaluable plasma or urine concentration data for azacitidine. This analysis was performed for participants in the 2 treatment groups who received azacitidine treatment for 5 days.

Groups in this outcome

Normal RF: Azacitidine 75 mg/m^2

Participants with normal renal function (RF) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.

Severe RI: Azacitidine 75 mg/m^2

Participants with severe renal impairment (RI) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Normal RF: Azacitidine 75 mg/m^26
Severe RI: Azacitidine 75 mg/m^26

Reported measurements

Day 1
Values in liters/hour · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Normal RF: Azacitidine 75 mg/m^2151.5530.88Not reportedNot reportedNot reported
Severe RI: Azacitidine 75 mg/m^285.7668.83Not reportedNot reportedNot reported
Day 5
Values in liters/hour · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Normal RF: Azacitidine 75 mg/m^2166.9527.59Not reportedNot reportedNot reported
Severe RI: Azacitidine 75 mg/m^2111.5551.75Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        30.88
        value
        151.55
      2. group Id
        OG001
        spread
        68.83
        value
        85.76
    title
    Day 1
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        27.59
        value
        166.95
      2. group Id
        OG001
        spread
        51.75
        value
        111.55
    title
    Day 5
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      6
    units
    Participants
description
The apparent total clearance of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated as Dose/AUC0-inf.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants with normal renal function (RF) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.
    id
    OG000
    title
    Normal RF: Azacitidine 75 mg/m^2
  2. description
    Participants with severe renal impairment (RI) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.
    id
    OG001
    title
    Severe RI: Azacitidine 75 mg/m^2
param Type
GEOMETRIC_MEAN
population Description
Pharmacokinetic Population, consisting of all participants with evaluable plasma or urine concentration data for azacitidine. This analysis was performed for participants in the 2 treatment groups who received azacitidine treatment for 5 days.
reporting Status
POSTED
time Frame
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
title
Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine
type
PRIMARY
unit Of Measure
liters/hour

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice